MG
Therapeutic Areas
Eagle Pharmaceuticals Pipeline
| Drug | Indication | Phase |
|---|---|---|
| BARHEMSYS® (amisulpride) injection | Postoperative nausea and vomiting (PONV) | Approved/Commercial |
| BYFAVO® (remimazolam) for injection | Induction and maintenance of procedural sedation | Approved/Commercial |
| CAL02 | Severe community-acquired bacterial pneumonia (adjunctive treatment) | Phase 2 |
| ENA-001 | Agnostic respiratory stimulant for respiratory depression (Post-operative, Community Drug Overdose, Apnea of Prematurity) | Phase 1 / Preclinical |
| EA-114 | Hormone-receptor-positive (HR+) metastatic breast cancer | Pre-NDA |
| Docetaxel Injection Non-Alcohol Formula | Oncology (various cancers) | Approved/Commercial |
Leadership Team at Eagle Pharmaceuticals
CK
Christopher Krawtschuk
Chief Financial Officer
DH
Debra Hussain
Head of Commercial for Acute Care/Hospital
DO
Daniel O'Connor
Chief Strategy Officer, Head of Corporate Development
JS
Jennifer Simpson, PhD
Board Member, Lead Independent Director, Compensation Committee Chair
RA
Richard A. Edlin, J.D.
Board Member, Nominating and Corporate Governance Committee Chair
RL
Robert L. Glenning
Board Member, Audit Committee Chair
LB
Luciana Borio, MD
Board Member, Strategic Clinical Development Committee Chair
SR
Steven Ratoff
Board Member